-
Detection of a Novel Safety Signal for Atorvastatin Potential Association With Hilar Lymphadenopathy Using FAERS Disproportionality Analysis and Molecular Docking
Sep 9, 2025, 16:22 PM -
Exploring the Use and Perception of Patient-Reported Outcome Evidence Among Cardiologists and Patients With Heart Failure
Sep 9, 2025, 16:22 PM -
What Counts? Exploring Stakeholder Perspectives on the Value of Guiding Criteria for Prioritizing Public Funding of Health Technologies
Sep 9, 2025, 16:22 PM -
Clinical Evidence Quality in Appraisals of Drugs for Rare Diseases in England and Germany
Sep 9, 2025, 16:22 PM -
Incidence of Intracerebral Hemorrhage in Patients With Mild Cognitive Impairment or Alzheimer’s Dementia in United States Veterans
Sep 9, 2025, 16:22 PM -
Prefilled Syringes in Anesthesiology: A Quantitative Assessment of Economic and Organizational Outcomes
Sep 9, 2025, 16:22 PM -
Reported Herpes Zoster Incidence Rates in Immunocompromised Adults Aged 18 Years or Older in England by Ethnicity and Socioeconomic Status: A Large Retrospective Cohort Study
Sep 9, 2025, 16:22 PM -
Integrating Health Equity Into Health Technology Assessment: A Scoping Review
Sep 9, 2025, 16:22 PM -
Safety Profile of Semaglutide in Obesity Management With or Without Type 2 Diabetes (T2DM): A Systematic Literature Review From Controlled and Real-World Settings
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness Analysis of Entrectinib in First-Line Treatment for NTRK Locally Advanced or Metastatic NSCLC in China
Sep 9, 2025, 16:22 PM -
Health Economic Analysis of Risk- and Age-Based Pneumococcal Vaccination With PCV21 vs. PCV20 in France
Sep 9, 2025, 16:22 PM -
Automation-Only Is NOT AI: Beware, HEOR Colleagues
Sep 9, 2025, 16:22 PM -
Navigating Parallel Joint Scientific Consultations Under EU HTA Regulation: Key Internal Considerations for Health Technology Developers
Sep 9, 2025, 16:22 PM -
Access and Evolving Evidence: A European HTA Analysis of Innovative Medicines Under Evidence Generation Agreements
Sep 9, 2025, 16:22 PM -
Simulation-Guided Trial Planning of a Cluster Randomized Trial With Probabilistic Covariate-Constrained Randomization for Vaccine Coverage
Sep 9, 2025, 16:22 PM -
An Algorithm to Identify Immunocompromised Patients in French Claims Data for Rapid Preventive or Therapeutic Interventions
Sep 9, 2025, 16:22 PM -
Extension of the Mammographic Screening Program in Italy: Cost-Benefit Analysis and Impact of Early Diagnosis in the 45-74 Age Group
Sep 9, 2025, 16:22 PM -
Assessing Productivity in Health Technology Assessment: A Comparative Review of Human Capital and Friction Cost Approaches in Europe
Sep 9, 2025, 16:22 PM -
Evaluating the Costs and Benefits of Innovative Pricing and Payment Models in Europe
Sep 9, 2025, 16:22 PM -
Cost-Utility of Intramuscular Testosterone for Men and Male Adolescents With Organic Hypogonadotropic Hypogonadism in Brazil
Sep 9, 2025, 16:22 PM
